Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

End-of-day quote. End-of-day quote  - 08/17
35.5 USD   +0.51%
03:40p PFIZER : N.j. to get $12m in wyeth settlement
03:18p FUN AHEAD : Kids at play
12:02pDJAstraZeneca's Investment Eats Into Profit -- 2nd Update
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Pfizer Inc. : Pfizer Gets Positive Opinion from EMA on Leukemia Drug Bosutinib

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/18/2013 | 02:46pm CEST
   By Saabira Chaudhuri 
 

Pfizer Inc. (>> Pfizer Inc.) said the European Medicines Agency (EMA) issued a positive opinion about the conditional marketing authorization of its cancer drug bosutinib in the European Union for the treatment of adult patients with certain types of leukemia.

Pfizer said the positive opinion was adopted by the Committee for Medicinal Products for Human Use and relates to chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor and for whom imatinib, nilotinib and dasatinib aren't considered appropriate treatment options.

Conditional approvals in the EU are granted to medicinal products with a positive benefit/risk assessment that address unmet medical needs and whose availability would result in a significant public health benefit.

Bosutinib is an oral, once-daily, kinase inhibitor, which limits cancer cell growth by inhibiting certain signaling pathways.

Pfizer noted that chronic myelogenous leukemia accounts for 15% of all leukemia cases and that, despite the availability of existing treatments for the condition, there remains a need for additional treatment options.

"We believe that bosutinib, if approved by the European Commission, would represent an important option for patients with CML who have progressed on prior treatment and are not candidates for alternative treatments," said Mace Rothenberg, senior vice president of clinical development and medical affairs at the Pfizer Oncology Business Unit. "We believe many doctors and CML patients will find this treatment, if approved, to be a welcome addition, offering a distinct adverse event profile and a convenient once-daily dosing regimen."

Shares were flat at $26.83 in recent premarket trading. The stock has risen 22% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on PFIZER INC
03:40p PFIZER : N.j. to get $12m in wyeth settlement
03:18p FUN AHEAD : Kids at play
12:02pDJAstraZeneca's Investment Eats Into Profit -- 2nd Update
10:35aDJAstraZeneca's Investment Eats Into Profit
10:28aDJAstraZeneca's Investment Eats Into Profit -- Update
04/28 Abbott deal for St. Jude spurs company split talk
04/28 PFIZER : Wyeth and Pfizer Agree to Pay $784.6 Million to Resolve Lawsuit Allegin..
04/28 PFIZER : Hosts Annual Meeting of Shareholders
04/28 PFIZER : State News Roundup
04/28 PFIZER : Shareholders criticize Pfizer after scrapped Allergan deal
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials